Clinical trial · Observational
HPV Genotype Attribution and Disease Burden of Anal Cancer in China
Understanding the Human Papillomavirus Genotype Attribution and Disease Burden of Anal Cancer in China: A Multicenter Hospital-based Study
NCT06670495CI-TRIAL-00103085recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To demonstrate HPV prevalence and its genotype distributions in anal cancer in China and to describe demographic and clinical features of HPV-related anal cancer in China; To describe the epidemiological characteristics ,trends and of disease burden of anal cancer in China
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Prevalence and types of distribution of HPV
- timeFrame
- From enrollment to pre-treatment
- measure
- Incidence of anal-cancers-associated complications
- timeFrame
- From enrollment to pre-treatment
- description
- with or without HPV infection by subgroups of sex, age at diagnosis, sexual orientation, and stage at diagnosis (Stage I, II, III, IV, unknown)
- measure
- Routine laboratory testing results
- timeFrame
- From enrollment to pre-treatment
Secondary outcomes (3)
- measure
- Incidence rates of anal cancer in China
- timeFrame
- From enrollment to pre-treatment
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * (1) Patients diagnosed with anal cancers, (2) Patients without radiation or chemotherapy prior to specimen collection; Exclusion Criteria: * (1) Patients with HIV infection, (2) Patients with immunosuppression after solid organ transplantation, (3) Those who do not agree to specimen collection and testing, (4) For retrospective study cases, those who without specimen.
References
Publications (0)
Data not yet available
No reference posted for this study.